Gsk Plc (GSK) Return on Assets ROA from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Gsk Plc  (NYSE: GSK)


Gsk Plc's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Gsk Plc's ROA in the fourth quarter of 2025?
Gsk Plc achieved a return on average assets (ROA) of 10.09 % in its fourth quarter of 2025, this is above GSK's average return on assets of 8.88%.
Gsk Plcs assets during the 12 months ending in the fourth quarter of 2025 are valued at $82 billion

ROA has improved compared to 3.77% in the third quarter of 2025, due to net income growth.

However, within the Healthcare sector 110 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 677.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Total Assets Change 24.09 % 10.38 % 10.38 % 10.38 % -11.92 %
Y / Y Net Income Change 181.14 % - - - -81.11 %
Net Income (TTM) in million 8,296 2,951 2,951 2,951 2,951
Return On Assets (TTM) 10.09 % 3.77 % 3.87 % 3.97 % 4.08 %
GSK's Total Ranking # 677 # # # # 1403
Total Assets (TTM) in million 82,185 82,185 82,185 82,185 66,228
Seq. Total Assets Change 0 % 0 % 0 % 24.09 % -11.05 %
Seq. Net Income Change - - - - -

GSK's 5 Years Annual ROA >> Back to GSK Management Effectiveness >> Compare GSK ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 44
Sector # 111
Overall # 670

Return On Assets Statistics
High Average Low
25.97 %
8.88 %
4.77 %
(Dec 31 2022)   (Dec 31 2021)





Financial Statements
Gsk Plc's Assets $ 82,185 million GSK's Balance sheet
Gsk Plc's Income $ 8,296 million Quarterly GSK's Income Statement
GSK's Income by Division See GSK's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 2.78 % -20.92 % 25.01 % -43.68 % -2.82 %
Total Assets in million 61,118 59,463 75,190 60,146 106,789
Y / Y Net Income Change 113.11 % -55.31 % -57.73 % 206.53 % -20.23 %
Net Income in million 6,289 2,951 6,603 15,621 5,096
Annual Return On Assets 10.29 % 4.96 % 8.78 % 25.97 % 4.77 %

GSK's 5 Years Annual ROA >> Back to GSK Management Effectiveness >> Compare GSK ROA to its Competitors



Comment on GSK's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 10.29 % compared to prior year, due to annual net income growth of 113.11 % to $6,289.00 million, while value of Gsk Plc's overall assets grew just by 2.78 % to $61,118.00 million, compared to $61,118.00 a year before.


More Return On Assets Ratios
GSK's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
GSK's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for GSK's Competitors
Subscribers only: Roa for Gsk Plc's Suppliers
Subscribers only: Return On Assets for GSK's Customers

You may also want to know
GSK's Roi GSK's Inventory Turnover Ratio GSK's Growth Rates GSK's Dividend Comparisons
GSK's Profitability Ratios GSK's Asset Turnover Ratio GSK's Dividend Growth
GSK's Roe GSK's Valuation Ratios GSK's Financial Strength Ratios GSK's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector ROA
Hutchmed china Limited  26.11 %
Petros Pharmaceuticals inc   26.04 %
Adma Biologics Inc   25.98 %
Theravance Biopharma inc   25.35 %
Ptc Therapeutics inc   25.21 %
Qhslab Inc   25.12 %
Rafael Holdings Inc  25.07 %
Medpace Holdings Inc   25.07 %
Mettler toledo International Inc   25.07 %
Compugen Ltd  22.57 %
Lifemd Inc   21.39 %
Catalyst Pharmaceuticals Inc   21.24 %
Iradimed Corporation  20.83 %
Incyte Corporation  20.70 %
Transmedics Group Inc   20.34 %
Eli Lilly And Company  19.76 %
Innoviva Inc   19.19 %
Novo Nordisk A  18.87 %
Resmed Inc   18.44 %
Pro dex Inc   18.07 %
Zoetis Inc   17.92 %
Inspire Medical Systems inc   17.91 %
United Therapeutics Corporation  17.29 %
Krystal Biotech Inc   17.12 %
Electromed Inc   16.83 %
Arrowhead Pharmaceuticals Inc   16.32 %
Vertex Pharmaceuticals Inc  16.23 %
Chemed Corporation  16.06 %
Mimedx Group Inc   15.89 %
Sbc Medical Group Holdings Incorporated  15.69 %

Date modified: 2026-09-09T12:36:18+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.